Numerous diseases are associated with abnormal or excessive angiogenesis, among them ocular diseases, cancer, rheumatoid arthritis, vascular malformations, diabetic nephropathy, and obesity, to name a few. Anti-angiogenic therapies have shown efficacy in ocular diseases and cancer. We are developing the next generation anti-angiogenic and anti-lymphangiogenic therapies that combine short therapeutic biomimetic peptides with delivery by biodegradable phagocytosis-resistant micro- and nanoparticles. We envision numerous applications of these novel therapeutics as monotherapies or in combination with existing drugs.
Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (also known as “wet” AMD) is the most prevalent cause of severe vision less in the elderly. This condition affect more than 1.75 million people in the United States and more than 12 million people worldwide. Due to the aging population, the incidence of Neovascular Age-Related Macular Degeneration is forecasted to increase by 50% by the year 2020. Current therapies are ineffective for some patients and the frequent injections required are a burden and carry a safety risk for all patients. AsclepiX Therapeutics addresses this in two main ways:
Solid tumors are dependent on angiogenesis for delivery of oxygen and nutrients required for their growth and metastasis. Tumor cells migrate into blood and lymphatic vessels and disseminate to other organs and tissues where they can originate metastatic growth.
AsclepiX platform technologies are applied to create cancer-specific anti-angiogenic and anti-lymphangiogenic nanomedicines to be used as neoadjuvant and adjuvant therapies to inhibit tumor growth and metastasis.
AsclepiX Therapeutics in leveraging recently developed immunomodulatory technology to regulate the immune system and improve the safety and efficacy of tissue transplantation.